Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
280.8 SEK | -0.43% | -0.92% | +5.17% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 28.74 times its 2024 earnings per share.
- The company's enterprise value to sales, at 4.5 times its current sales, is high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.17% | 8.87B | B+ | ||
-2.47% | 88.14B | A- | ||
+3.29% | 40.44B | A- | ||
-15.40% | 32.24B | B- | ||
+51.96% | 24.39B | A | ||
-14.35% | 15.59B | C | ||
-39.65% | 12.3B | B | ||
-6.52% | 12.18B | D+ | ||
-13.41% | 12.14B | B- | ||
-6.67% | 8.41B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SOBI Stock
- Ratings Swedish Orphan Biovitrum AB